The Next Wave of TIDES: Market Growth, Manufacturing Scale-Up, and the CDMO Industry Outlook
View our Complimentary White Book
The global market for peptide and oligonucleotide (TIDES) medicines is expanding as these therapies reach broader patient populations. The commercial success of GLP-1 therapies has driven widespread use of peptide drugs in metabolic disease, while advances in drug delivery are helping extend oligonucleotide development beyond rare diseases into areas such as cardiovascular and metabolic disease. As demand grows, drugmakers face the challenge of producing increasingly complex molecules at commercial scale while maintaining consistent quality and a reliable supply.
Contract development and manufacturing organizations (CDMOs) are playing a larger role in that transition, helping drugmakers develop manufacturing processes, characterize products, and scale up from clinical batches to commercial volumes. As regulatory requirements evolve, manufacturing technology advances, and global supply chains remain uncertain, drugmakers are weighing a broader range of factors when selecting CDMO partners. Global leading CDMOs increasingly stand out for their track record of bringing complex molecules into commercial production, executing technology transfers, and supplying multiple markets reliably while meeting stringent quality and regulatory requirements.
Against this backdrop, Frost & Sullivan and Medtide Inc., a global CRDMO specializing in peptide and oligonucleotide, have jointly released the 2026 Global Peptide and Oligonucleotide Drug Industry White Paper. The report examines the forces driving market expansion, the manufacturing capabilities needed to support commercial growth, and the trends shaping the future of the global CDMO industry.
Download this complimentary White book to discover:
Global Market Development of Peptide and Oligonucleotide Therapeutics:
An overview of the global peptide and oligonucleotide drug markets, covering market growth, commercialized products, clinical pipelines, key therapeutic areas and technological developments.
Manufacturing Processes and CDMO Outsourcing Needs:
An analysis of peptide and oligonucleotide manufacturing processes, including chemical synthesis, purification, analytical characterization and scale-up requirements. The report explores how increasing molecular complexity and commercialization needs are driving demand for specialized CDMO services, alongside evolving outsourcing models and customer requirements across different stages of drug development.
TIDES Supply Chain Risks and Regulatory Trends:
An examination of the global TIDES supply chain, covering critical raw materials, manufacturing capacity, supply chain risks and mitigation strategies. The report also reviews evolving regulatory frameworks, quality management requirements and environmental compliance trends, highlighting their implications for TIDES manufacturers and CDMO providers.
Global TIDES CDMO Landscape and Future Technology Trends:
An overview of the global TIDES CDMO landscape, featuring leading companies such as WuXi AppTec, CordenPharma, PolyPeptide, Agilent and Medtide, with a focus on service models, manufacturing capabilities and global service networks. The report also examines capacity expansion and emerging technology trends, including the gradual adoption of continuous manufacturing, digital process and quality management systems and AI applications, alongside key considerations in selecting CDMO partners.


